A GPS system to target diseased tissue more accurately.

We create therapeutics that know their way round the biological map and know exactly which cells to target.

Poor targeting limits the potential of promising therapies

Most drugs in clinical testing fail. 50% fail due to poor efficacy, because too little reaches the right place.

30% fail due to toxicity build-up in healthy tissues.

We give drugs access to an expanded biological map

For many areas of the body, there is no map, no postcode (antigen), meaning drugs fail to reach their intended destination.

Xterna leverages a new class of biological postcode (antigen), enabling our drug linked navigators, XENAs, to reach previously challenging areas of the body.

XENAs are designed using alternative nucleic acids

Built from xeno nucleic acids (XNAs), XENAs combine programmable targeting with the properties needed to operate in a demanding biological environment. This enables XENAs to guide diverse therapeutic cargoes with enhanced durability and specificity compared to conventional approaches.

We provide earlier in vivo insight at scale

Xterna’s proprietary platform enables in vivo XENA discovery at scale, providing detailed insight into tissue distribution and post-administration clearance for XENA-targeted therapeutics.

By revealing how therapeutic candidates behave in vivo earlier in the discovery process, Xterna enables broader, more informed candidate screening, identifying the most promising drug profiles sooner and reducing time wasted on advancing less effective compounds.